Do analysts recommend BJDX or ICU?

SeaStar Medical has a consensus price target of $8.00, suggesting a potential upside of 158.90%. Given SeaStar Medical's stronger consensus rating and higher possible upside, analysts clearly believe SeaStar Medical is more favorable than Bluejay Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SeaStar Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer TMDIF or BJDX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TMDIF or BJDX more profitable?

Titan Medical's return on equity of -82.31% beat Bluejay Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Titan Medical N/A -82.31% -51.47% Bluejay Diagnostics N/A -125.00% -99.79%

Do analysts rate IRIX or BJDX?

IRIDEX currently has a consensus target price of $3.00, indicating a potential upside of 324.63%. Given IRIDEX's stronger consensus rating and higher possible upside, research analysts plainly believe IRIDEX is more favorable than Bluejay Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IRIDEX 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate ADGM or BJDX?

Adagio Medical presently has a consensus price target of $3.50, indicating a potential upside of 584.93%. Given Adagio Medical's stronger consensus rating and higher probable upside, analysts plainly believe Adagio Medical is more favorable than Bluejay Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adagio Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ADGM or BJDX more profitable?

Bluejay Diagnostics' return on equity of -125.00% beat Adagio Medical's return on equity. Company Net Margins Return on Equity Return on Assets Adagio Medical N/A -661.85% -73.35% Bluejay Diagnostics N/A -125.00% -99.79%

Does the media refer more to ADGM or BJDX?

In the previous week, Adagio Medical had 1 more articles in the media than Bluejay Diagnostics. MarketBeat recorded 4 mentions for Adagio Medical and 3 mentions for Bluejay Diagnostics. Adagio Medical's average media sentiment score of 0.47 beat Bluejay Diagnostics' score of 0.08 indicating that Adagio Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adagio Medical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bluejay Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate HSCS or BJDX?

HeartSciences currently has a consensus target price of $8.00, indicating a potential upside of 164.03%. Given HeartSciences' stronger consensus rating and higher probable upside, equities analysts clearly believe HeartSciences is more favorable than Bluejay Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HSCS or BJDX more profitable?

Bluejay Diagnostics' return on equity of -125.00% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets HeartSciences N/A -358.60% -144.82% Bluejay Diagnostics N/A -125.00% -99.79%

Bluejay Diagnostics (BJDX) Competitors

$0.90 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Compare

BJDX vs. ICU, TMDIF, IRIX, ADGM, and HSCS

Should you buy Bluejay Diagnostics stock or one of its competitors? Bluejay Diagnostics's main competitors and comparable companies include SeaStar Medical (ICU), Titan Medical (TMDIF), IRIDEX (IRIX), Adagio Medical (ADGM), and HeartSciences (HSCS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Bluejay Diagnostics compare to SeaStar Medical?

Bluejay Diagnostics (NASDAQ:BJDX) and SeaStar Medical (NASDAQ:ICU) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Bluejay Diagnostics has a net margin of 0.00% compared to SeaStar Medical's net margin of -795.51%. Bluejay Diagnostics' return on equity of -125.00% beat SeaStar Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-125.00%	-99.79%
SeaStar Medical	-795.51%	-162.75%	-109.89%

Bluejay Diagnostics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, SeaStar Medical has a beta of -1.05, suggesting that its stock price is 205% less volatile than the broader market.

SeaStar Medical has a consensus price target of $8.00, suggesting a potential upside of 158.90%. Given SeaStar Medical's stronger consensus rating and higher possible upside, analysts clearly believe SeaStar Medical is more favorable than Bluejay Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SeaStar Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 1.7% of SeaStar Medical shares are held by institutional investors. 6.1% of Bluejay Diagnostics shares are held by insiders. Comparatively, 0.7% of SeaStar Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Bluejay Diagnostics has higher earnings, but lower revenue than SeaStar Medical. SeaStar Medical is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$7.11	N/A
SeaStar Medical	$1.71M	7.95	-$12.15M	-$3.91	N/A

In the previous week, Bluejay Diagnostics had 2 more articles in the media than SeaStar Medical. MarketBeat recorded 3 mentions for Bluejay Diagnostics and 1 mentions for SeaStar Medical. SeaStar Medical's average media sentiment score of 0.93 beat Bluejay Diagnostics' score of 0.08 indicating that SeaStar Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Bluejay Diagnostics	Neutral
SeaStar Medical	Positive

Summary

Bluejay Diagnostics beats SeaStar Medical on 9 of the 15 factors compared between the two stocks.

How does Bluejay Diagnostics compare to Titan Medical?

Titan Medical (NASDAQ:TMDIF) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Titan Medical has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

In the previous week, Bluejay Diagnostics had 3 more articles in the media than Titan Medical. MarketBeat recorded 3 mentions for Bluejay Diagnostics and 0 mentions for Titan Medical. Bluejay Diagnostics' average media sentiment score of 0.08 beat Titan Medical's score of 0.00 indicating that Bluejay Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Titan Medical	Neutral
Bluejay Diagnostics	Neutral

Titan Medical's return on equity of -82.31% beat Bluejay Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	-82.31%	-51.47%
Bluejay Diagnostics	N/A	-125.00%	-99.79%

0.0% of Titan Medical shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 0.0% of Titan Medical shares are owned by company insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Titan Medical has higher revenue and earnings than Bluejay Diagnostics. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63M	0.80	$6.95M	$0.05	2.47
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$7.11	N/A

Summary

Titan Medical beats Bluejay Diagnostics on 7 of the 12 factors compared between the two stocks.

How does Bluejay Diagnostics compare to IRIDEX?

IRIDEX (NASDAQ:IRIX) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

IRIDEX currently has a consensus target price of $3.00, indicating a potential upside of 324.63%. Given IRIDEX's stronger consensus rating and higher possible upside, research analysts plainly believe IRIDEX is more favorable than Bluejay Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

IRIDEX has higher revenue and earnings than Bluejay Diagnostics. IRIDEX is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IRIDEX	$52.67M	0.24	-$4.44M	-$0.20	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$7.11	N/A

IRIDEX has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

In the previous week, Bluejay Diagnostics had 2 more articles in the media than IRIDEX. MarketBeat recorded 3 mentions for Bluejay Diagnostics and 1 mentions for IRIDEX. IRIDEX's average media sentiment score of 0.44 beat Bluejay Diagnostics' score of 0.08 indicating that IRIDEX is being referred to more favorably in the media.

Company	Overall Sentiment
IRIDEX	Neutral
Bluejay Diagnostics	Neutral

20.1% of IRIDEX shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 8.6% of IRIDEX shares are owned by insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bluejay Diagnostics has a net margin of 0.00% compared to IRIDEX's net margin of -6.88%. IRIDEX's return on equity of 0.00% beat Bluejay Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IRIDEX	-6.88%	N/A	-12.55%
Bluejay Diagnostics	N/A	-125.00%	-99.79%

Summary

IRIDEX beats Bluejay Diagnostics on 11 of the 15 factors compared between the two stocks.

How does Bluejay Diagnostics compare to Adagio Medical?

Adagio Medical (NASDAQ:ADGM) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

Adagio Medical has a beta of -0.15, suggesting that its stock price is 115% less volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

Bluejay Diagnostics has lower revenue, but higher earnings than Adagio Medical. Adagio Medical is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagio Medical	$600K	18.92	-$25.08M	-$1.48	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$7.11	N/A

In the previous week, Adagio Medical had 1 more articles in the media than Bluejay Diagnostics. MarketBeat recorded 4 mentions for Adagio Medical and 3 mentions for Bluejay Diagnostics. Adagio Medical's average media sentiment score of 0.47 beat Bluejay Diagnostics' score of 0.08 indicating that Adagio Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adagio Medical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bluejay Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adagio Medical presently has a consensus price target of $3.50, indicating a potential upside of 584.93%. Given Adagio Medical's stronger consensus rating and higher probable upside, analysts plainly believe Adagio Medical is more favorable than Bluejay Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagio Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

48.1% of Adagio Medical shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 7.8% of Adagio Medical shares are owned by company insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Bluejay Diagnostics' return on equity of -125.00% beat Adagio Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagio Medical	N/A	-661.85%	-73.35%
Bluejay Diagnostics	N/A	-125.00%	-99.79%

Summary

Adagio Medical beats Bluejay Diagnostics on 10 of the 14 factors compared between the two stocks.

How does Bluejay Diagnostics compare to HeartSciences?

HeartSciences (NASDAQ:HSCS) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

HeartSciences has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

Bluejay Diagnostics has lower revenue, but higher earnings than HeartSciences. HeartSciences is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	$4.32K	2,735.35	-$9.14M	-$3.94	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$7.11	N/A

In the previous week, Bluejay Diagnostics had 1 more articles in the media than HeartSciences. MarketBeat recorded 3 mentions for Bluejay Diagnostics and 2 mentions for HeartSciences. HeartSciences' average media sentiment score of 1.44 beat Bluejay Diagnostics' score of 0.08 indicating that HeartSciences is being referred to more favorably in the media.

Company	Overall Sentiment
HeartSciences	Positive
Bluejay Diagnostics	Neutral

17.2% of HeartSciences shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 4.9% of HeartSciences shares are owned by insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bluejay Diagnostics' return on equity of -125.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-358.60%	-144.82%
Bluejay Diagnostics	N/A	-125.00%	-99.79%

HeartSciences currently has a consensus target price of $8.00, indicating a potential upside of 164.03%. Given HeartSciences' stronger consensus rating and higher probable upside, equities analysts clearly believe HeartSciences is more favorable than Bluejay Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

HeartSciences and Bluejay Diagnostics tied by winning 7 of the 14 factors compared between the two stocks.

Get Bluejay Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BJDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BJDX vs. The Competition

Export

Metric	Bluejay Diagnostics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.02M	$5.78B	$7.18B	$12.89B
Dividend Yield	N/A	1.75%	2.54%	11.28%
P/E Ratio	-0.13	25.92	273.17	25.45
Price / Sales	N/A	79.02	637.71	104.31
Price / Cash	N/A	33.69	28.74	36.03
Price / Book	0.11	6.18	11.08	6.36
Net Income	-$6.85M	$149.94M	$3.48B	$349.79M
7 Day Performance	-0.02%	-0.22%	0.38%	-0.40%
1 Month Performance	4.65%	6.39%	7.89%	4.24%
1 Year Performance	-83.47%	6.29%	24.71%	15.13%

Bluejay Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BJDX Bluejay Diagnostics	1.1474 of 5 stars	$0.90 flat	N/A	-83.5%	$4.02M	N/A	N/A	9	Analyst Downgrade Gap Up
ICU SeaStar Medical	2.6616 of 5 stars	$3.11 -2.2%	$8.00 +157.2%	-66.3%	$13.72M	$1.23M	N/A	2
TMDIF Titan Medical	N/A	$0.12 -2.3%	N/A	-61.6%	$13.19M	$17.63M	N/A	50
IRIX IRIDEX	1.6636 of 5 stars	$0.68 -4.5%	$3.00 +338.6%	-47.3%	$12.02M	$52.67M	N/A	120
ADGM Adagio Medical	2.6411 of 5 stars	$0.52 -4.7%	$3.50 +567.9%	-68.3%	$11.64M	$600K	N/A	87	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BJDX) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bluejay Diagnostics (BJDX) Competitors

BJDX vs. ICU, TMDIF, IRIX, ADGM, and HSCS

How does Bluejay Diagnostics compare to SeaStar Medical?

Summary

How does Bluejay Diagnostics compare to Titan Medical?

Summary

How does Bluejay Diagnostics compare to IRIDEX?

Summary

How does Bluejay Diagnostics compare to Adagio Medical?

Summary

How does Bluejay Diagnostics compare to HeartSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BJDX vs. The Competition

Bluejay Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bluejay Diagnostics (BJDX) Competitors

BJDX vs. ICU, TMDIF, IRIX, ADGM, and HSCS

How does Bluejay Diagnostics compare to SeaStar Medical?

Is BJDX or ICU more profitable?

Which has more risk and volatility, BJDX or ICU?

Do analysts recommend BJDX or ICU?

Do insiders and institutionals hold more shares of BJDX or ICU?

Which has preferable valuation and earnings, BJDX or ICU?

Does the media prefer BJDX or ICU?

Summary

How does Bluejay Diagnostics compare to Titan Medical?

Do analysts prefer TMDIF or BJDX?

Which has more risk and volatility, TMDIF or BJDX?

Does the media favor TMDIF or BJDX?

Is TMDIF or BJDX more profitable?

Do institutionals and insiders believe in TMDIF or BJDX?

Which has higher valuation and earnings, TMDIF or BJDX?

Summary

How does Bluejay Diagnostics compare to IRIDEX?

Do analysts rate IRIX or BJDX?

Which has preferable valuation & earnings, IRIX or BJDX?

Which has more volatility and risk, IRIX or BJDX?

Does the media refer more to IRIX or BJDX?

Do insiders and institutionals believe in IRIX or BJDX?

Is IRIX or BJDX more profitable?

Summary

How does Bluejay Diagnostics compare to Adagio Medical?

Which has more volatility & risk, ADGM or BJDX?

Which has better earnings and valuation, ADGM or BJDX?

Does the media refer more to ADGM or BJDX?

Do analysts rate ADGM or BJDX?

Do insiders & institutionals believe in ADGM or BJDX?

Is ADGM or BJDX more profitable?

Summary

How does Bluejay Diagnostics compare to HeartSciences?

Which has more risk and volatility, HSCS or BJDX?

Which has higher valuation and earnings, HSCS or BJDX?

Does the media refer more to HSCS or BJDX?

Do institutionals and insiders believe in HSCS or BJDX?

Is HSCS or BJDX more profitable?

Do analysts rate HSCS or BJDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BJDX vs. The Competition

Bluejay Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools